<DOC>
	<DOCNO>NCT01963663</DOCNO>
	<brief_summary>Patients type 2 diabetes increase risk develop atherosclerosis , largely due underlie insulin resistance chronic low grade inflammation . Cardiovascular event could prevent proper intervention target ameliorate aforementioned detrimental process . YKL-40 , novel surrogate marker acute chronic inflammatory state implicate putative role pathway . Given share pathway insulin resistance atherosclerosis , conceivable anti-diabetes medication able modify coronary artery disease risk via direct indirect amelioration YKL-40 concentration . The present clinical trial therefore launch examine comparative effect metformin pioglitazone , two commonly prescribe anti-diabetes medication YKL-40 concentration medication-na√Øve , newly-diagnosed type 2 diabetes patient .</brief_summary>
	<brief_title>Metformin Pioglitazone Effects YKL-40 Concentrations Type 2 Diabetes Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>CHI3L1 protein , human</mesh_term>
	<criteria>Newly diagnose type 2 diabetes patient base American Diabetes Association criterion diagnosis diabetes positive history take antidiabetes medication class past positive current history take overthecounter vitamin antioxidant supplement presence clinically significant chronic illness heart , lung , kidney .</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>YKL-40</keyword>
	<keyword>Chronic low grade inflammation</keyword>
	<keyword>type 2 diabetes mellitus</keyword>
	<keyword>metformin</keyword>
	<keyword>pioglitazone</keyword>
</DOC>